论文部分内容阅读
目的:分析联合检测乳腺癌易感基因1(BRCA1)及细胞角蛋白19(CK19)对乳腺癌的诊断及治疗效果评估的临床价值。方法:选取该科2010年1月~2014年6月收治的126例乳腺癌患者,同时选取同期健康女性120例。对比两组血清BRCA1及CK19水平。分析BRCA1及CK19单项及联合检测对于乳腺癌诊断的价值。对比乳腺癌患者手术前后的BRCA1及CK19水平。结果:乳腺癌组的血清BRCA1及CK19水平显著高于健康女性组,P<0.01。联合检测BRCA1及CK19可将诊断灵敏度提高至92.86%,但特异度无明显变化。乳腺癌患者术后血清BRCA1及CK19水平显著低于术前,P<0.01。结论:联合检测BRCA1及CK19对乳腺癌的诊断及治疗效果评估具有重要意义。
Objective: To analyze the clinical value of combined detection of breast cancer susceptibility gene 1 (BRCA1) and cytokeratin 19 (CK19) in the diagnosis and treatment of breast cancer. Methods: A total of 126 patients with breast cancer admitted to our hospital from January 2010 to June 2014 were enrolled, and 120 healthy women were selected at the same time. The serum levels of BRCA1 and CK19 were compared between the two groups. To analyze the value of single and combined detection of BRCA1 and CK19 in the diagnosis of breast cancer. The levels of BRCA1 and CK19 in breast cancer patients before and after surgery were compared. Results: The serum levels of BRCA1 and CK19 in breast cancer patients were significantly higher than those in healthy women (P <0.01). The combined detection of BRCA1 and CK19 increased the diagnostic sensitivity to 92.86%, but the specificity did not change significantly. The serum levels of BRCA1 and CK19 in patients with breast cancer were significantly lower than those before operation (P <0.01). Conclusion: The combined detection of BRCA1 and CK19 is of great importance in the diagnosis and treatment of breast cancer.